Bayer is advancing its industry-leading transparency commitments in 2020, starting with additional documents on the transparency website and the pilot launch of OpenLabs.
This step builds on the company's pledge to enhance transparency by making its product safety studies required for regulatory approval accessible to the public.
'Transparency is at the core of how we operate as the leading provider of innovative and sustainable solutions in agriculture,' said
GM Seeds &
Bayer will expand the scope of its transparency commitments starting in
The second new information module is on plant breeding. Innovation in plant breeding, such as gene editing, helps farmers provide the world with enough food by growing crops that are more resilient to a changing climate, while also using less resources and pesticides.
OpenLabs
OpenLabs is a new visitor program that provides a unique opportunity to observe Bayer scientists at the Monheim,
'By expanding the scope of our efforts in transparency, we are reinforcing our commitment to continually raising the bar on transparency standards around our agricultural innovations in every area where we work,' said
More details on Bayer's commitments to transparency, sustainability and engagement can be found on the company's website.
Background
Bayer launched its transparency program in
US regulatory submission documents assessed by the
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Contact:
Tel: +1 314-694-3247
(C) 2020 Electronic News Publishing, source